Clinical trials: Disturbed Sleep
Sleep, Sleep Disturbance
An Exploratory Investigation of a Supplement to Enhance Sleep Quality and Quantity
This double-blind study will examine the effectiveness of Dream Powder and Dream Powder Extra Strength over a six week period. The main outcomes of interest will be sleep quantity and quality, as well as self-reported changes in…
- Conditions
- Sleep, Sleep Disturbance, Sleep Hygiene
- Trial name
- NCT05521243
- Testing
- Beam Organics Dream Powder, Beam Organics Dream Powder Extra Strength
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Beam
Sleep Disturbance, Insomnia
Closed Loop TES for Enhancing Slow Wave Sleep
Compare closed-loop with open-loop application of TES to enhance slow waves of sleep.
- Trial name
- NCT03751982
- Testing
- Transcranial Electrical Neuromodulation (TES)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Brain Electrophysiology Laboratory Company
Adult Nocturnal Enuresis, Urinary Incontinence (UI)
This Study Will Collect Clinical and Patient Reported Experience Data From Participants Requiring Urine Output Management Overnight in the Home Setting.
This post-market study will assess the performance of and user experience with the PureWick™ System in a home setting. The study will also observe safety of the study device and collect information from participants about their…
- Trial name
- PUREST (NCT06666426)
- Testing
- PureWick System, Hollister Female Urinary Pouch External Collection Device
- Where
- 15 sites in United States
- Volunteers
- 171 people
- Sponsor
- C. R. Bard
Short-term Insomnia
Pilot Study of a Combination Drug Product for Treatment of Short-term Insomnia
The purpose of this study is to evaluate the effect of a combination drug product containing diphenhydramine, zolpidem and lorazepam on total sleep time.
- Trial name
- NCT02671760
- Testing
- SM-1, Comparator
- Volunteers
- 39 people
- Sponsor
- Sequential Medicine Ltd
Nocturnal Symptoms of GERD, Sleep Disorders in GERD
QUality of Sleep Improvement With Evening Topical Therapy for Non-Erosive Gastroesophageal Reflux Disease (The QUIET Trial)
The goal of this randomized, double-blind, single-center clinical trial is to learn if medical devices work to decrease nocturnal symptoms of GERD gastroesophageal reflux disease in adults' patients and improve sleeping time…
- Conditions
- Nocturnal Symptoms of GERD, Sleep Disorders in GERD, GERD (Gastroesophageal Reflux Disease), Non-Erosive Gastro-Esophageal Reflux Disease
- Trial name
- QUIET (NCT07700342)
- Where
- 2 sites in Poland
- Volunteers
- 50 people
- Sponsor
- Cellmedis
Sleep Disturbance, Sleep Quality
A Exploratory Study of NatureU Sweet Dream on Sleep Outcomes
This was a single-center, open-label, exploratory self-controlled study evaluating NatureU Sweet Dream on sleep outcomes in adults with mild to moderate sleep disturbance.
- Trial name
- NUSD (NCT07600528)
- Testing
- NatureU Sweet Dream, Commercially Available Melatonin Product
- Where
- China
- Volunteers
- 17 people
- Sponsor
- OmniSolutions Laboratory Holdings Limited
Restless Legs Syndrome
A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS
The primary objective of this study is to investigate the effects on RLS symptoms and sleep disturbance of pramipexole (Mirapexin) 0.125 mg/day to 0.75 mg/day per os for 12 weeks, compared to placebo, in the treatment of patients…
- Trial name
- NCT00349531
- Testing
- Pramipexole
- Where
- 49 sites in Denmark, Finland and 7 more
- Volunteers
- 369 people
- Sponsor
- Boehringer Ingelheim
Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance
The purpose of this study is to assess the efficacy and safety of GSK1838262 extended release tablets in the treatment of patients with Restless Legs Syndrome and associated sleep disturbance.
- Trial name
- NCT00748098
- Testing
- GSK1838262 Extended Release Tablets
- Where
- 24 sites in United States
- Volunteers
- 136 people
- Sponsor
- XenoPort, Inc.
Sleep Disturbances
Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder
To assess effects of brexpiprazole on sleep patterns of depressed patients with sleep disturbances.
- Trial name
- NCT01942733
- Testing
- Brexpiprazole
- Volunteers
- 44 people
- Sponsor
- H. Lundbeck A/S
Parkinson Disease
Parkinson's Disease Progression Study
Disease Progression Study
- Trial name
- NCT06219629
- Where
- 10 sites in United States
- Volunteers
- 82 people
- Sponsor
- Koneksa Health
Fatigue, Stress
The U.K. Embryologist Fatigue Study
The purpose of the study is to determine physical and mental health issues of U.K. embryologists related to their occupational characteristics, and how workplace fatigue and burnout may affect their quality of life, cynicism…
- Conditions
- Fatigue, Stress, Burnout, Professional, Musculoskeletal Pain
- Trial name
- FUSE-UK (NCT05708963)
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- TMRW Life Sciences
Autism Spectrum Disorder, Sleep Disorder
Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
This is a multicenter, open-label study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon in treating sleep disturbances in pediatric and adult participants with ASD.
- Conditions
- Autism Spectrum Disorder, Sleep Disorder, Neurological Disorder, Sleep Disturbance
- Trial name
- NCT05361707
- Testing
- Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension
- Where
- 5 sites in United States
- Volunteers
- 100 people
- Sponsor
- Vanda Pharmaceuticals
Sleep Disturbance, Insomnia
The CANabidiol Use for RElief of Short Term Insomnia
This study aims to investigate the effect of 50 mg and 100 mg per day oral CBD product versus a placebo over 8 weeks on insomnia severity in adults aged 18-65 years old with insomnia symptoms.
- Conditions
- Sleep Disturbance, Insomnia, Insomnia Type; Sleep Disorder, Insomnia, Transient
- Trial name
- CANREST (NCT05253417)
- Testing
- 50 mg Cannabidiol (CBD), 100 mg Cannabidiol (CBD)
- Where
- 2 sites in Australia
- Volunteers
- 208 people
- Sponsor
- Bod Australia
Inflammatory Bowel Diseases, Depressive Episode
Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health
This study is a large population-based analysis in the United Kingdom (UK) using routine primary care data to investigate the impacts on quality-of-life outcomes and use of healthcare services in people aged 5 - 25 years…
- Conditions
- Inflammatory Bowel Diseases, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorder
- Trial name
- NCT05206734
- Testing
- No specific intervention
- Where
- United Kingdom
- Volunteers
- 19,469 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Gastroesophageal Reflux
A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn
The purpose of this study is to determine whether Dexlansoprazole once daily (QD) is effective in treating patients with night heartburn.
- Trial name
- NCT00627016
- Testing
- Dexlansoprazole
- Where
- 43 sites in United States
- Volunteers
- 305 people
- Sponsor
- Takeda
Psychological Stress, Sleep Disturbance
Sleep More, Stress Less: 90-Day Trial of Neuralli Mood
This decentralized, single-arm study evaluates the effects of 90 days of daily Neuralli Mood supplementation on perceived stress, sleep disturbance, mood, anxiety, depressive symptoms, happiness, and occupational burnout in…
- Conditions
- Psychological Stress, Sleep Disturbance, Anxiety Symptoms, Depressive Symptoms
- Trial name
- NM90 (NCT07717385)
- Testing
- Neuralli Mood
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Efforia, Inc
Atopic Dermatitis, Sleep Disturbance
A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis
Many people with atopic dermatitis (AD) experience sleep disturbances. Greater sleep disturbances are associated with greater burden including increased sick days and impaired cognition.
- Trial name
- Sleep Up (NCT06390722)
- Testing
- Upadacitinib
- Sponsor
- AbbVie
Alzheimer's Disease, Sleep Disorder
Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
The aim of this exploratory randomized, placebo controlled study is to evaluate the efficacy of Circadin® 2mg in patients with mild to moderate Alzheimer Disease (AD) treated with the acetylcholinesterase (AChE) inhibitor.
- Trial name
- NCT00940589
- Testing
- Circadin
- Where
- 6 sites in United States, Israel and 1 more
- Volunteers
- 73 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Insomnia (moderate)
Impact of GABA Probiotic Lactiplantibacillus Plantarum Lp815 on Sleep Outcomes in Participants with Self-Reported Sleep Disturbance
The rationale for this study is to observe differences in sleep outcomes between a consumer-grade probiotic capsule called GABA Probiotic and a placebo control group.
- Trial name
- NCT06789718
- Testing
- GABA Probiotic Lactiplantibacillus plantarum Lp815 (5 Billion cfu/dose), Optional Sub-Study: Neurotransmitter Urine Test
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Verb Biotics LLC
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19
A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection
This is a Phase 2, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken once daily at bedtime for the management…
- Conditions
- Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID
- Trial name
- PREVAIL (NCT05472090)
- Testing
- TNX-102 SL
- Where
- 29 sites in United States
- Volunteers
- 63 people
- Sponsor
- Tonix Pharmaceuticals, Inc.